SCHEMBL4265699

SCHEMBL4265699

Nc1nc(N)c2c(-c3ccc4[nH]ccc4c3)nn(-c3ccc4[nH]ccc4c3)c2n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 5/20 0.52
ABL1 P00519 5/20 0.52
EGFR P00533 5/20 0.52
HCK P08631 5/20 0.52
SRC P12931 5/20 0.52
KDR P35968 5/20 0.52
PIK3CA P42336 5/20 0.52
PIK3CB P42338 5/20 0.52
MTOR P42345 5/20 0.52
PIK3CG P48736 5/20 0.52
EPHB4 P54760 5/20 0.52
PRKDC P78527 5/20 0.52
PI4KB Q9UBF8 2/20 0.52
FYN P06241 1/20 0.46
PTK6 Q13882 1/20 0.44
ATR Q13535 2/20 0.44
MAP3K11 Q16584 1/20 0.41
TGFBR1 P36897 6/20 0.40
KCNH2 Q12809 1/20 0.40
GRM1 Q13255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4267729 0.83 KDR (0.53) PIK3CDABL1EGFRHCKSRC
SCHEMBL846923 0.72 BRD4 (0.47) PIK3CDABL1EGFRHCKSRC
SCHEMBL27612533 0.71 PIK3CD (0.46) PIK3CDABL1EGFRHCKSRC
SCHEMBL129497 0.71 PIK3CD (0.83) PIK3CDABL1EGFRHCKSRC
SCHEMBL4267300 0.70 DYRK1A (0.45) PIK3CAMTORTGFBR1
SCHEMBL2315798 0.68 SRC (1.00) PIK3CDABL1EGFRHCKSRC
SCHEMBL4269315 0.67 SRC (0.52) PIK3CDABL1EGFRHCKSRC
SCHEMBL14574776 0.66 PIK3CD (1.00) PIK3CDABL1EGFRHCKSRC
SCHEMBL23251820 0.65 FYN (0.65) PIK3CDABL1EGFRHCKSRC
SCHEMBL1640616 0.65 BRAF (0.58) PIK3CDABL1EGFRHCKSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090076037-A1 BICYCLIC PYRIMIDINE KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-19 US claimed
WO-2008039359-A2 BICYCLIC PYRIMIDINE KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-04-03 WO claimed
US-8314234-B2 Bicyclic pyrimidine kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2012-11-20 US disclosed
US-20090076037-A1 BICYCLIC PYRIMIDINE KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-19 US disclosed
WO-2008039359-A2 BICYCLIC PYRIMIDINE KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076037-A1 BICYCLIC PYRIMIDINE KINASE INHIBITORS DCK, CDK2, DTYMK PIK3CD 96/4885ABL1 161/4885EGFR 1356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.